Personalis Inc. is a biotechnology company that specializes in advanced genomic sequencing and data analytics for precision medicine. The company was founded in 2011 by a group of scientists and researchers with extensive expertise in genomics and bioinformatics. It is based in Menlo Park, California, and has since become a leader in providing genomic information and insights to support the development of personalized therapies and treatments for various diseases. The company is listed on the Nasdaq Stock Market under the ticker symbol "PSNL."
Personalis offers a comprehensive suite of services, including whole-genome sequencing, whole-exome sequencing, and RNA sequencing, among others. These services enable researchers, pharmaceutical companies, and healthcare providers to gain a deeper understanding of an individual's genetic makeup and its potential implications on disease development and treatment response.
Personalis offers its, ImmunoID NeXT Platform. This platform combines genomic sequencing with advanced bioinformatics and data analytics to profile both the tumor and the immune system of cancer patients. By analyzing both aspects simultaneously, the ImmunoID NeXT Platform provides comprehensive insights into the tumor's genetic characteristics and the patient's immune response. This information is crucial in identifying potential targets for immunotherapies and predicting patient response to specific treatments, thus paving the way for more effective and personalized cancer treatments.
The company's cutting-edge technology and its dedication to advancing precision medicine have attracted collaborations with renowned pharmaceutical companies, academic institutions, and research organizations. As the field of genomics and personalized medicine continues to evolve, Personalis remains at the forefront, driving innovations that have the potential to significantly impact patient care and treatment outcomes.